MAPS — Randomized Controlled Phase 3 Trial for PTSD therapy (2019)

Organization:
Multidisciplinary Association for Psychedelic Studies
Award Date:
08/2019
Amount:
$500,000
Purpose:
To support a randomized controlled trial testing the use of MDMA-assisted therapy to treat post-traumatic stress disorder.

Good Ventures awarded a grant of $500,000 to the Multidisciplinary Association for Psychedelic Studies (MAPS) for continued support for a randomized controlled trial testing the use of MDMA-assisted psychotherapy to treat post-traumatic stress disorder. Research on psychedelics appears to be a neglected and potentially important aspect of drug policy reform, and it's our impression that MAPS is one of the leading nonprofits undertaking research on possible medical uses for psychedelics.

This grant is part of our work on drug policy reform.

Read more: